Long-term potency preservation following brachytherapy for prostate cancer.

摘要: UNLABELLED: Study Type - Therapy (case series). Level of Evidence 4. What's known on the subject? and What does study add? Previously, rates potency preservation with or without external beam radiation and/ hormone therapy have been published smaller series limited follow-up. The provides greater numbers longer follow-up giving patients clinicians a better appreciation true in this population how various factors such as age, use affect those rates. OBJECTIVES: • To assess men following brachytherapy for prostate cancer (EBRT) and/or androgen deprivation (ADT). evaluate that significantly impact rate. PATIENTS AND METHODS: In all, 1063 potent T1-T3 were treated from 1990 to 2007 seed implantation alone ((103) Pd (125) I) (69.6%) combined modality treatment consisting partial dose (103) implant followed 6-8 weeks later by EBRT (45 Gy, prostate/seminal vesicles only) (30.4%). ADT was used 49.1% cases (range 1-27 months). Patients required minimum 2 years be off 1 year. Erectile function assessed prior at each visit using physician-assigned Mount Sinai Function Score (MSEFS): 0, unable erections; 1, erections insufficient intercourse; 2, suboptimal but sufficient 3, normal erectile function. Potent defined score than equal phosphodiesterase type 5 inhibitor. rate calculated actuarial methods comparisons tested log-rank Cox regression analysis. RESULTS: 5-year 10-year 68.0% 57.9%, respectively, last On multivariate analysis, 5- 87.6% (79.5%) younger 60, (57.5%) age 60-70, 42.2% (31.0%) older 70 (P < 0.001). Pretreatment MSEFS had 51.7% (37.2%) vs 74.2% (65.2%) an 3 There 75.8% (62.6%) 60.0% (53.0%) Five-year 76.4% alone, 71.0% EBRT, 62.2% ADT, 57.9% CONCLUSION: Increasing initial implant, diminished pretreatment combination increases dysfunction brachytherapy.